Tricks of the TradeTrump's Second TermMy EconomyI've Always Wondered ...

Loading...

0:00
0% played
Support the fact-based journalism you rely on with a donation to Marketplace today. Give Now!
Stories Tagged as

Pfizer

COVID-19

AstraZeneca vaccine is third to show promising data in unprecedented hurry-up race

by Scott Tong
Nov 23, 2020
The COVID-19 vaccine is being produced so quickly due to a combination of factors involving the research community, government, industry and the public.
A volunteer receives a COVID-19 vaccination at the Research Centers of America in Hollywood, Florida.
Chandan Khanna/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

Pfizer to ask today for emergency vaccine authorization

by David Brancaccio , Jasmine Garsd and Alex Schroeder
Nov 20, 2020
Emergency authorization means the FDA facilitates availability of the vaccine during a declared state of emergency.
An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes with the logo of pharmaceutical company Pfizer, on Nov. 17, 2020.
Justin Tallis/AFP via Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

How might COVID-19 vaccine makers compete in the marketplace?

by Andy Uhler
Nov 17, 2020
At first, COVID-19 vaccines won't be marketed in the usual sense, because the government will be the main buyer.
A volunteer takes part in a COVID-19 vaccination trial this summer in Hollywood, Florida.
Joe Raedle/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
COVID-19

How much could Pfizer make from a COVID-19 vaccine?

by Janet Nguyen
Nov 12, 2020
A COVID vaccine from the pharmaceutical company has been shown to be highly promising.
A view of a Pfizer building in Puurs, Belgium.
Jean-Christophe Guillaume/Getty Images
Share Now on:
SHARE
COVID-19

Why Pfizer says it pushed for transparency and diversity in vaccine development process

by Scott Tong
Nov 9, 2020
To build public trust, Pfizer shared details of their trials: who was tested, the race and ethnicity of participants, how they were monitored, how to measure success and funding sources.
A person walks by Pfizer headquarters on Nov. 9, 2020, in New York City. Transparency is key for a vaccine-skeptical public.
David Dee Delgado/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Generic Viagra floods the market. Here’s how Pfizer is reacting

by Dan Gorenstein
Jul 13, 2018
Pfizer hopes to run with its “little blue pill” as long as it can. That includes the time-honored strategy of launching its own generic.
Christopher Furlong/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

The Trump administration wants drug companies to lower prices. This is what’s actually happening.

by Dan Gorenstein
Jul 5, 2018
Pfizer recently raised the list prices for more than 40 of its prescription medications, including the pain med Lyrica. It’s the second time this year Pfizer has boosted list prices. The increases come at a time of increased public and political scrutiny over drug prices. Is Big Pharma not feeling the heat? Click the above […]
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

For public good, not for profit.

Donate

Big Pharma's competition to buy new cancer drugs

by Jed Kim
Aug 22, 2016
Pfizer spends $14 billion for a new prostate cancer drug plus others in the pipeline
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

The only way to stop inversions might be tax reform

by Dan Gorenstein
Apr 6, 2016
The Pfizer-Allergan merger is out, but what about inversions across the board?
Pfizer was set to merge with Allergan, but after new inversion rules announced by the Treasury Department, the phama giants decided against merging. 
Spencer Platt/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Pfizer abandons $160B Allergan deal

by Marketplace Staff
Apr 6, 2016
A change in U.S. tax laws has put a halt to the merger.
The outside of Pfizer's headquarters.
Mario Tama/Getty Images
Share Now on:
SHARE